Blyth Christopher C, Cheng Allen C, Finucane Carolyn, Jacoby Peter, Effler Paul V, Smith David W, Kelly Heath, Macartney Kristine K, Richmond Peter C
School of Paediatrics and Child Health, University of Western Australia, Perth, Australia; Department of Infectious Diseases, Princess Margaret Hospital for Children, Perth, Australia; Department of Microbiology, PathWest Laboratory Medicine WA, Princess Margaret Hospital for Children, Perth, Australia; Wesfarmers Centre for Vaccines and Infectious Diseases, Telethon Kids Institute, University of Western Australia, Perth, Australia.
Infection Prevention and Healthcare Epidemiology Unit, Alfred Health, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia.
Vaccine. 2015 Dec 16;33(51):7239-7244. doi: 10.1016/j.vaccine.2015.10.122. Epub 2015 Nov 6.
There is increasing evidence demonstrating influenza vaccine effectiveness (VE) in the prevention of influenza in children, including the very young. Data demonstrating the effectiveness against severe disease, including hospitalisation, are limited. We aimed to determine the VE of the southern hemisphere trivalent inactivated influenza vaccine (TIV) in preventing laboratory-confirmed influenza-associated hospitalisation in children.
Laboratory records were used to identify children with confirmed influenza hospitalised (i.e., cases) during a 5 year period (2008, 2010-2013) at the only tertiary paediatric facility in Western Australia. Cases and time, age and ward matched controls were retrospectively reviewed to determine risk factors, vaccination status and outcome. Adjusted odds ratios and VE estimates were derived using conditional logistic regression models.
Three hundred and eighty five cases were identified (Influenza A, 64.9%; Influenza B, 35.1%). Influenza-like illness and pneumonia were the most frequent presentation (74.5% and 23.9%, respectively). The median length of stay was 2 days (Interquartile range 1-4 days). Twenty children (5.2%) required admission to the intensive care unit. Vaccine uptake in cases and controls was low (4.9% and 8.5%, respectively). Three hundred and six case-control pairs were included in the VE analysis, of which 19 pairs were informative with discrepant vaccination status. VE (fully vaccinated vs. unvaccinated) was estimated to be 62.3% (95% CI: -6.6%, 86.7%).
In this study, the point estimate for the effectiveness of TIV in preventing influenza-associated hospitalisation in children was similar to that reported for emergency or outpatient attended, laboratory-confirmed influenza, yet confidence intervals were wide. Vaccine uptake remains low. Studies, enroling larger numbers of children, ideally with higher vaccine uptake, are needed to provide additional evidence on TIV protection against influenza hospitalisation in children.
越来越多的证据表明流感疫苗在预防儿童(包括幼儿)流感方面具有有效性。然而,证明其对包括住院在内的严重疾病有效性的数据有限。我们旨在确定南半球三价灭活流感疫苗(TIV)预防儿童实验室确诊的流感相关住院的有效性。
利用实验室记录来识别在西澳大利亚唯一的三级儿科机构中,5年期间(2008年、2010 - 2013年)确诊流感住院的儿童(即病例)。对病例以及时间、年龄和病房匹配的对照进行回顾性分析,以确定危险因素、疫苗接种状况和结局。使用条件逻辑回归模型得出调整后的比值比和有效性估计值。
共识别出385例病例(甲型流感,64.9%;乙型流感,35.1%)。流感样疾病和肺炎是最常见的表现(分别为74.5%和23.9%)。中位住院时间为2天(四分位间距1 - 4天)。20名儿童(5.2%)需要入住重症监护病房。病例组和对照组的疫苗接种率较低(分别为4.9%和8.5%)。有效性分析纳入了306对病例对照,其中19对在疫苗接种状况上存在差异,可提供信息。估计疫苗有效性(全程接种与未接种相比)为62.3%(95%可信区间:-6.6%,86.7%)。
在本研究中,TIV预防儿童流感相关住院有效性的点估计值与急诊或门诊就诊的实验室确诊流感报告值相似,但可信区间较宽。疫苗接种率仍然较低。需要开展纳入更多儿童、理想情况下疫苗接种率更高的研究,以提供关于TIV预防儿童流感住院保护作用的更多证据。